0001140361-23-029142.txt : 20230609 0001140361-23-029142.hdr.sgml : 20230609 20230609163047 ACCESSION NUMBER: 0001140361-23-029142 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henrich Jill CENTRAL INDEX KEY: 0001978096 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 231005790 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 3 1 form3.xml X0206 3 2023-06-01 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001978096 Henrich Jill C/O ATARA BIOTHERAPEUTICS, INC. 2380 CONEJO SPECTRUM STREET, SUITE 200 THOUSAND OAKS CA 91320 true EVP, Global Head RA & Quality Common Stock 111037 D Employee Stock Option (Right to Buy) 13.46 2023-05-08 2030-09-07 Common Stock 40000 D Employee Stock Option (Right to Buy) 13.46 2030-09-07 Common Stock 20000 D Employee Stock Option (Right to Buy) 17.105 2023-06-01 2031-02-28 Common Stock 19416 D Employee Stock Option (Right to Buy) 17.105 2031-02-28 Common Stock 15103 D Employee Stock Option (Right to Buy) 10.21 2023-06-01 2032-02-29 Common Stock 16601 D Employee Stock Option (Right to Buy) 10.21 2032-02-29 Common Stock 36525 D Employee Stock Option (Right to Buy) 3.91 2023-06-01 2033-02-28 Common Stock 7869 D Employee Stock Option (Right to Buy) 3.91 2033-02-28 Common Stock 86564 D Includes an aggregate 79,169 restricted stock units ("RSUs"), which are comprised of: (i) 11,256 RSUs that vest as to 1/6th of shares on August 15, 2023, and each of the next five (5) Quarterly Vesting Dates (as defined herein); (ii) 10,008 RSUs that vest as to 1/7th of shares on August 15, 2023 and each of the next six (6) Quarterly Vesting Dates; (iii) 19,432 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates; and (iv) 38,473 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates, each of which is subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the "Quarterly Vesting Date" shall be the first (1st) business day after such date. 1/16th of shares subject to the stock option vest and become exercisable on June 8, 2023, and the remaining shares vest in equal monthly installments over the following fifteen (15) months, subject to the reporting person's continuous service. 1/21st of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following twenty (20) months, subject to the reporting person's continuous service. 1/33rd of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-two (32) months, subject to the reporting person's continuous service. Exhibit 24 - Power of Attorney /s/ Jeff Kiekhofer, Attorney-in-Fact for Jill Henrich 2023-06-09 EX-24 2 brhc20054258_ex24.htm EXHIBIT 24
Exhibit 24
 
POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints Eric Hyllengren, Jeff Kiekhofer, Amar Murugan, John Chao and Kathleen Klaben the undersigned's true and lawful attorneys-in-fact to:

1.         Complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and

2.        Do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.
 
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

The undersigned hereby terminates all prior powers of attorney regarding the subject matter hereof.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 10, 2023.

 
Signature:
/s/ Jill Henrich
   
Jill Henrich